Kolexia
Botsen Damien Oncologie médicale
Botsen Damien
Oncologie médicale
Institut Godinot
Reims, France
80 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Adénocarcinome Tumeurs colorectales Tumeurs gastro-intestinales Tumeurs de l'appareil digestif Sarcopénie Tumeurs du pancréas Malnutrition COVID-19 Faiblesse musculaire

Collaborateurs

Voir plus
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Brasseur Mathilde
Brasseur Mathilde
Hôpital Robert-Debré Reims, Reims, France
Mazza Camille
Mazza Camille
Institut Godinot, Reims, France
Perrier Marine
Perrier Marine
Hôpital Robert-Debré Reims, Reims, France

Industries

Voir plus
Amgen
13 collaboration(s)
Dernière en 2023
Servier
10 collaboration(s)
Dernière en 2023
Pierre Fabre
10 collaboration(s)
Dernière en 2023
Merck-Serono
9 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
TASKIN: Multicentric Randomized Phase I/II Study to Evaluate Efficacy of Trifluridine/Tipiracil Plus XB2001 (Anti-IL-1α True Human Antibody) Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine
Essai Clinique (Centre Georges-François Leclerc)   12 février 2024
CAPANCOVID-19: Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer
Essai Clinique (CHU Reims)   23 janvier 2024
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   17 janvier 2024
SAFIR-ABC10: Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
Essai Clinique (Taiho Oncology, Inc.)   15 novembre 2023
GEMPAX: A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma
Essai Clinique (Unicancer)   07 novembre 2023
LOGICAN: Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With Gastric, Oesophagus or Gastroesophageal Junction Adenocarcinoma Locally Advanced, Recurrent or Metastatic, Ineligible for Triplet Chemotherapy
Essai Clinique (Servier)   12 octobre 2023
LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1555P Cell-free DNA analysis in patients with metastatic gastroesophageal adenocarcinoma: Preliminary results of the REGIRI - PRODIGE 58 ancillary study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
NEXT-REGIRI: A Randomized Phase III Trial Assessing a Regorafenib-irinotecan Combination (REGIRI) Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients After Failure of Standard Therapies, According to the A/A Genotype of Cyclin D1
Essai Clinique (Institut du Cancer de Montpellier)   26 septembre 2023